Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Yarnoff

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
BMJ Open|January 31, 2024
Descriptive analysis to assess seasonal patterns of COVID-19 and influenza in low-income and middle-income countries in Asia, the Middle East and Latin AmericaMoe H Kyaw, Julia Regazzini Spinardi, Oladayo Jagun, et al.
Preventing Chronic Disease|February 5, 2021
Validation of the Prevention Impacts Simulation Model (PRISM)Benjamin Yarnoff, Amanda Honeycutt, Christina Bradley, et al.
Journal of Medical Economics|March 27, 2026
Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United StatesAlon Yehoshua, Manuela Di Fusco, Abby E Rudolph, et al.
Journal of Medical Economics|November 13, 2024
Public health and economic impact of COVID-19 vaccination with the Pfizer-BioNTech COVID-19 Vaccine, KP.2, among adults in 2024/2025 in the United StatesAlon Yehoshua, Manuela Di Fusco, Abby E Rudolph, et al.
Diabetes, Obesity & Metabolism|June 3, 2026
Cost-Effectiveness of NT-proBNP-Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real-World Evidence From the Hong Kong Diabetes BiobankAbby Q Y Li, Benjamin Yarnoff, Claudia H T Tam, et al.
Journal of Medical Economics|October 21, 2024
Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineagesAlon Yehoshua, Angela D Cook, Manuela Di Fusco, et al.
Preventing Chronic Disease|October 4, 2019
Estimating Costs of Implementing Stroke Systems of Care and Data-Driven Improvements in the Paul Coverdell National Acute Stroke ProgramBenjamin Yarnoff, Olga Khavjou, Joanna Elmi, et al.
Expert Review of Vaccines|December 17, 2022
Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical dataJingyan Yang, Shailja Vaghela, Benjamin Yarnoff, et al.
Expert Review of Vaccines|December 7, 2024
Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi ArabiaNadine Al Akoury, Julia Spinardi, Hammam Haridy, et al.
Expert Review of Vaccines|June 26, 2026
Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican RepublicCarlos Fernando Mendoza, Juan José Baldi-Castro, Moe H Kyaw, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
BMJ Open|January 31, 2024
Descriptive analysis to assess seasonal patterns of COVID-19 and influenza in low-income and middle-income countries in Asia, the Middle East and Latin AmericaMoe H Kyaw, Julia Regazzini Spinardi, Oladayo Jagun, et al.
Preventing Chronic Disease|February 5, 2021
Validation of the Prevention Impacts Simulation Model (PRISM)Benjamin Yarnoff, Amanda Honeycutt, Christina Bradley, et al.
Journal of Medical Economics|March 27, 2026
Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United StatesAlon Yehoshua, Manuela Di Fusco, Abby E Rudolph, et al.
Journal of Medical Economics|November 13, 2024
Public health and economic impact of COVID-19 vaccination with the Pfizer-BioNTech COVID-19 Vaccine, KP.2, among adults in 2024/2025 in the United StatesAlon Yehoshua, Manuela Di Fusco, Abby E Rudolph, et al.
Diabetes, Obesity & Metabolism|June 3, 2026
Cost-Effectiveness of NT-proBNP-Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real-World Evidence From the Hong Kong Diabetes BiobankAbby Q Y Li, Benjamin Yarnoff, Claudia H T Tam, et al.
Journal of Medical Economics|October 21, 2024
Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineagesAlon Yehoshua, Angela D Cook, Manuela Di Fusco, et al.
Preventing Chronic Disease|October 4, 2019
Estimating Costs of Implementing Stroke Systems of Care and Data-Driven Improvements in the Paul Coverdell National Acute Stroke ProgramBenjamin Yarnoff, Olga Khavjou, Joanna Elmi, et al.
Expert Review of Vaccines|December 17, 2022
Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical dataJingyan Yang, Shailja Vaghela, Benjamin Yarnoff, et al.
Expert Review of Vaccines|December 7, 2024
Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi ArabiaNadine Al Akoury, Julia Spinardi, Hammam Haridy, et al.
Expert Review of Vaccines|June 26, 2026
Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican RepublicCarlos Fernando Mendoza, Juan José Baldi-Castro, Moe H Kyaw, et al.
Pageof 4